Study the immune responses after pertussis vaccination in adults
- Conditions
- Whooping cough, pertussis, vaccination, cellular immunity, humoral immunity
- Registration Number
- NL-OMON28859
- Lead Sponsor
- Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
• Good general health;
• 25-29 years of age;
Exclusion Criteria
• Antibiotic use within 14 days of enrollment;
• Present evidence of serious disease(s) demanding immunosuppressive medical treatment, like corticosteroids, that might interfere with the results of the study within the last 3 months;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method • To assess pertussis specific IgG antibody levels in serum at T0 (prior to vaccination), 14 days (T1), 28 days (T2), 1 year (T3) and 2 (T4) years after vaccination to determine the kinetics of pertussis specific antibody levels after an aP booster vaccination in adults 25-29 years of age;<br /><br>• To assess memory B- and T-cell responses against the various B. pertussis vaccine proteins at all time points to determine the effects of an aP booster vaccination in adults 25-29 years of age.<br>
- Secondary Outcome Measures
Name Time Method • To determine pertussis specific IgG-subclasses and –avidity in serum;<br /><br>• To determine pertussis specific IgG-antibodies in saliva;<br /><br>• To measure serum specific IgG-antibodies, and memory B- and T-cell responses against the other components (Diphtheria and Tetanus) of the booster vaccine;<br /><br>• To measure pertussis specific IgA antibodies in serum and saliva.